Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24606379 | 0.79 | — | — | |
| SCHEMBL13176792 | 0.77 | KDM4E (0.58) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL14724285 | 0.74 | EPHX1 (0.33) | — | |
| SCHEMBL378843 | 0.73 | KDM4E (0.54) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL1687734 | 0.73 | KDM4E (0.67) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL24910867 | 0.72 | HRH4 (0.33) | KDM4E | |
| SCHEMBL1900471 | 0.72 | KDM4E (0.82) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL860791 | 0.72 | KDM4E (0.94) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL21663261 | 0.72 | KDM4E (0.64) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL21534373 | 0.72 | ADRA1A (0.34) | KDM4EMAPK1HIF1AADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | KDM4E 3294/4885MAPK1 4411/4885HIF1A 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.